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Abstract
The emerging roles of microRNAs (miRs) have been deeply investigated in cancer. However, the role of
miR-194 in human laryngeal squamous cell carcinoma (LSCC) is still unclear. Here, we have demonstrated
that miR-194 is significantly downregulated in LSCC tissues and cells, and overexpression of miR-194 inhibits
the proliferation, migration, invasion, and drug resistance in LSCC cells. Moreover, Wee1 is identified as a
novel direct target of miR-194. Ectopic expression of Wee1 at least in part overcomes the suppressive
impacts of miR-194 on the malignant phenotypes of LSCC. Overall, our study provides new sights into the
role of miR-194/Wee1 axis in LSCC and suggests a novel miR-194/Wee1-based clinical application for LSCC
patients.
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Letter to the editor
Laryngeal cancer is the fourteenth most prevalent
type of malignancy worldwide in the male compared
to its relative rare in the female. Laryngeal squamous
cell carcinoma (LSCC) accounts for approximately
90% of all malignant tumors of the larynx [1].
Deregulated microRNAs (miRs) are frequently demon-
strated as biomarker or therapeutic target in LSCC tissues
and cells, which may function as tumor suppressor or
oncogene to regulate the malignancy of cancer [2]. As one
of frequently deregulated miRs in cancer, the expression
and role of miR-194 in LSCC are still unknown [3, 4].
In the current study, we found that the expression
level of miR-194 is significantly lower not only in two
LSCC cell lines Hep-2 and KB-3-1 compared with
normal human bronchial epithelial cell line 16HBE
but also in clinical LSCC tissues compared with adja-
cent normal tissues and correlated with T stage,
lymph node metastasis, and clinical stage, but not
with age, tumor grades, and tumor primary locations
(Fig. 1b–g, Additional file 1: Figure S1a and Table S1).
The miR-194 levels could be a significant parameter
to distinguish LSCC and adjacent normal tissues
with an area under the ROC curve (AUC) of 0.676
(sensitivity = 63.64%, specificity = 72.72%; P = 0.004)
(Fig. 1h). Kaplan–Meier analysis indicated that high
miR-194 expression predicts a favorable outcome for
LSCC patients (Fig. 1i). Functional assays showed that
enforced expression of miR-194 inhibits the growth,
migration, invasion, and drug resistance of Hep-2 and KB-
3-1 cells in vitro (Additional file 1: Figure S2a–g). The
data in the subcutaneous tumor model in nude mice
revealed that overexpression of miR-194 significantly
inhibited the growth of Hep-2 and KB-3-1 xenografts by
the numbers of Ki67+ proliferating cells and CD31+
microvessels (Additional file 1: Figure S3a–d). We used
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three computational algorithms, including miRanda,
PITA, and TargetScan in combination to identify the
novel potential targets of miR-194. All three algorithms
predicted Wee1 as a target gene of miR-194, which is a
protein kinase to regulate cell cycle through inhibiting
CDK1 by phosphorylation on its two different residues
Thr14 and Tyr15 [5]. Western blot analysis showed that
ectopic expression of miR-194 in Hep-2 and KB-3-1
cells obviously downregulated the protein levels of
Wee1 as well as the known targets XIAP and p27 [3, 6]
(Fig. 2a). The predicted interaction between miR-194
and the target sites within the 3’-untranslated regions
(3’UTR) of Wee1 was shown in Fig. 2b. We then per-
formed luciferase assay to examine whether there is a
direct interaction between miR-194 and Wee1. The
wild type or mutant 3’UTR region of Wee1 were cloned
into downstream of the firefly luciferase gene to
generate the luciferase reporter vectors. As illustrated
in Fig. 2c, ectopic expression of miR-194 significantly
decreased the luciferase activity of wild type 3’UTR, but
not mutant 3’UTR in Hep-2 and KB-3-1 cells, sug-
gesting that the putative miRNA binding sites of Wee1
are responsible for this miRNA-mRNA interaction
(Additional file 1: Figure S1b). Furthermore, analysis of
proteins extracted from Hep-2 and KB-3-1 subcutane-
ous tumors in mice exhibited that the protein levels of
Wee1 in miR-194-transduced tumors were remarkably
lower than those in vector control (Fig. 2d). In addition,
ectopic expression of Wee1 partially reverses the sup-
pressive effects of miR-194 on LSCC cells (Additional
file 1: Figure S4a–g).
In summary, our data reveal a potential suppressive
role of miR-194 in LSCC by targeting Wee1 in vitro
and in vivo. The clinical results indicate that miR-194
Fig. 1 Downregulation of miR-194 in LSCC is correlated with T stages, lymph node metastasis, clinical stages, recurrence, and poor
prognosis. a RT-qPCR analysis of the relative miR-194 expression in 44 pairs of LSCC tissues and adjacent normal tissues with Student’s t
test. The relative miR-194 expression in two groups of LSCC tissues classified by age (b), T stage (c), lymph node metastasis (f) and
clinical stage (g) were analyzed with Mann-Whitney U test. The relative miR-194 expression in three groups of LSCC tissues classified by
differentiation (d) and primary location (e) were analyzed with Kruskal–Wallis test. h ROC curve analysis of the discrimination between
LSCC tissues and adjacent normal tissues by miR-194. i Kaplan–Meier analysis of overall survival and disease-free survival curves for LSCC
patients with high and low expression of miR-194. Data are presented as mean ± SD or median with the interquartile range. *P < 0.05;
**P < 0.01; NS no statistical significance
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can be the potential diagnostic and prognostic bio-
markers for LSCC. Our study provides new sights
into the role of miR-194/Wee1 axis in LSCC and sug-
gests a novel miR-194/Wee1-based clinical application
for LSCC patients.
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Fig. 2 MiR-194 directly targets Wee1. a Western blot analysis of Wee1, XIAP, and p27 protein expressions in the indicated cells. GAPDH
is the loading control. b A schematic diagram of the reporter constructs showed the wild type (Wt) and mutant (Mut) sequences of the
miR-194 binding sites within human Wee1 3’-UTR. c Luciferase activity of reporters with Wee1 Wt or Mut 3’-UTR in the indicated cells.
d Western blot analysis and quantification of Wee1 protein expression in the tumors of the indicated cells. A-Tubulin was the loading
control. Data are presented as mean ± SD. Student’s t test was used for statistical analysis. **P < 0.01
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